Shopping Cart
Remove All
Your shopping cart is currently empty
CE-355621
😃Good
Catalog No. T9901A-1782
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.
CE-355621
CE-355621
😃Good
Catalog No. T9901A-1782
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer. |
| In vitro | CE-355621 is effective in blocking the binding of c-Met with HGF and induces c-Met degradation in A549 cells at concentrations ranging from 0.01 to 100 nM over 4 hours. At concentrations of 0.01 nM to 10 nM for 24 hours, CE-355621 significantly inhibits c-Met activation in U87MG cells. Additionally, it induces c-Met degradation in U87MG cells at concentrations of 0.01 to 10 μg/mL over a 48-hour period. |
| In vivo | Administered intraperitoneally, CE-355621 at doses ranging from 25-200 μg on days 0, 2, 3, 6, and 8 significantly delayed tumor growth in U87MG xenografts in female CD-1 nu/nu mice. Additionally, a dose of 400 μg on days 7 and 14 markedly inhibited tumor growth of GTL-16 xenografts in the same mouse model. A single dose of 200 μg on day 7 effectively reduced tumor volume growth and [18 F-FDG] uptake in U87MG xenografts in female nude mice (nu/nu). |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CE-355621 | purchase CE-355621 | CE-355621 cost | order CE-355621 | CE-355621 in vivo | CE-355621 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.